Overall verdict
Neutral
4.9/10
1-year performance
+35.30%
Score breakdown
Up 35.3% over 1 year, 84% of the 52-week range.
Strongest: Valuation 7.9/10. Weakest: Profitability 0.0/10.
27 analysts, target +0.1% vs the price.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus ;
Tecartus, a T-cell therapy for the treatment of adult patients ; Trodelvy, an injection for intravenous use ; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd. ; Abingworth ; Arcus Biosciences, Inc. ; Merck Sharp & Dohme Corp. ; Janssen Sciences Ireland Unlimited Company ; Japan Tobacco, Inc. ; Everest Medicines ; Merck & Co, Inc. ; Tentarix Biotherapeutics Inc. ; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Daniel Patrick O'Day
Founded
1987
Employees
17 000
Revenue / employee
1.7M USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- BlackRock, Inc.9.69%
- VANGUARD CAPITAL MANAGEMENT LLC6.45%
- FMR LLC5.32%
- STATE STREET CORP4.87%
- Capital World Investors3.26%
- Invesco Ltd.3.17%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.81%
- GEODE CAPITAL MANAGEMENT, LLC2.39%
- PRICE T ROWE ASSOCIATES INC /MD/2.39%
- Other institutions47.89%
- Rest of the register11.77%
2279 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
157.29 USD
52-week low
108.46 USD
1-year performance
35.30%
Rising
Year-to-date performance
23.58%
Rising
Drawdown
-5.10%
Mild pullback
Position in the 52-week range
84% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.1 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Gilead Sciences | 115 290 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.1 times as much as the world ETF.
- Worst fall:-47 % between July 2015 and December 2020. 10,000 € placed at the top fell to 5 288 €. The world ETF, at worst: -34 %. Back to its high in 23 months.
Gilead Sciences earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Gilead Sciences: 115 290 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 155.07 USD - 180.00 USD (3 methods agree)
The price implies growth of 0.78% per year; the company grows at 25.00%.
Gross margin 79.7%, the company loses 10.6% of its revenue, ROIC -8.4%, ROE -20.6%.
Net margin
-10.61%
Negative
Sector -15.62%|S&P 12.97%
Gross margin
79.66%
Fair
Return on equity (ROE)
-20.57%
Negative
Sector -19.44%|S&P 16.52%
Return on invested capital (ROIC)
-8.36%
Negative
Free cash flow margin (FCF)
42.37%
Exceptional
Margin stability
12.1 pts
Very uneven
Revenue to net income
Growth
2.3/10Revenue up 10.7% over 1 year, 3.6% a year over 5, EPS 133.6% a year over 5.
Revenue (trailing 12 months)
30.5Md USD
Revenue growth (1y)
10.73%
Solid
Revenue growth (3y)
8.72%
Moderate
EPS growth (1y)
-640.66%
Declining
EPS CAGR (5y)
133.64%
Exceptional
EPS revisions (3 months)
—
Valuation
7.9/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 29.6x|S&P 23.0x
Forward P/E
18.6x
Fair
EV / EBITDA
14.2x
Fair
Sector 23.4x|S&P 14.5x
PEG
—
Sector 0.12|S&P 0.86
Fair value (reverse DCF)
163.50 USD
Fairly priced
P/E vs its own 5-year history
among the 33% highest valuations
Pricier than usual
Market cap
188Md USD
Financial strength
4.3/10Cash covers 18.6% of the debt, net debt/EBITDA 1.1x.
Net debt / EBITDA
1.1x
Solid
Gearing (net debt / equity)
181.90%
Stretched
Cash
4.9Md USD
Cash / market cap
2.60%
Stretched
Cash / total debt
18.60%
Tight
Interest coverage
-2.5x
Stretched
Net debt
21.4Md USD
Equity
11.7Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 149.62 USD
- MM20148.45
- MM50141.18
- MM200135.84
- RSI 1457.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.90%
200-day average slope, 3 months
+4.81%
50-day average slope, 1 month
+6.33%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.33 % per day
Volatility change
-16.79%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -3.31 (12) | -0.43 (27) | 30 702 (25) | 7 859 (5) | -4 275 (7) |
| 2027 | 8.02 (12) | 9.89 (26) | 32 682 (24) | 17 834 (5) | 10 275 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 4 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 4.9 | 4.0 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 35.3 % | ||
| 7 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 8 | NTRA | 3.8 | 2.3 | 56.3Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 136.1 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
